MAPT and early-onset autosomal dominant Alzheimer disease: Diagnosing these patients during life can be done by measuring amyloid beta (Aβ) and phosphorylated tau (pTau) in the CSF or with PET to form an Alzheimer's disease factor (ADF) and using the diffusion MRI scan to indicate vascular damage to form a vascular disease factor (VDF).